Cell Biology and Toxicology

, Volume 28, Issue 6, pp 435–442 | Cite as

Benign prostate hyperplasia and stem cells: a new therapeutic opportunity

  • Maria NotaraEmail author
  • Aamir Ahmed


Most men over 50 experience some lower urinary tract symptoms of nocturia, poor stream, urgency and frequency for urination, due to hyperplastic enlargement of the prostate (benign prostate hyperplasia, BPH). BPH is thought to be a disease with multiple aetiologies including hormone signalling, disruption of proliferation and apoptosis dynamics and chronic inflammation with changes in the morphology and phenotype of the prostate stroma. It has been proposed, recently, that stromal stem cells in prostate may be caused by the development of BPH. This review focuses on this putative role of stromal stem or stem-like cells in the development of BPH and assesses the potential of targeting the stem cells for the treatment of BPH.


Benign prostate hyperplasia Drug targeting Stem cells Stroma 



Lower urinary tract symptoms


Benign prostate hyperplasia


Central zone




Mesenchymal stem cell


Peripheral zone


Stem cell


Stem cell antigen


Stromal stem cell


Transitional zone


Terminal deoxynucleotidyl transferase dUTP Nick end labelling



We would like to thank Prostate Action UK (AA and MN) and the Prostate Cancer Research Centre (AA) for their financial support.


  1. Barclay WW, Woodruff RD, Hall MC, Cramer SD. A system for studying epithelial–stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer. Endocrinology. 2005;146:13–8.PubMedCrossRefGoogle Scholar
  2. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474–9.PubMedGoogle Scholar
  3. Berry SJ, Coffey DS, Strandberg JD, Ewing LL. Effect of age, castration, and testosterone replacement on the development and restoration of canine benign prostatic hyperplasia. Prostate. 1986;9:295–302.PubMedCrossRefGoogle Scholar
  4. Burger PE, Xiong XH, Coetzee S, Salm SN, Moscatelli D, Goto K, Wilson EL. Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue. Proc Natl Acad Sci U S A. 2005;102:7180–5.PubMedCrossRefGoogle Scholar
  5. Claus S, Berges R, Senge T, Schulze H. Cell kinetic in epithelium and stroma of benign prostatic hyperplasia. J Urol. 1997;158:217–21.PubMedCrossRefGoogle Scholar
  6. Clifford GM, Farmer RDT. Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur Urol. 2000;38:2–19.PubMedCrossRefGoogle Scholar
  7. Cohen RJ, Glezerson G, Taylor LF, Grundle HAJ, Naude JH. The neuroendocrine cell-population of the human prostate-gland. J Urol. 1993;150:365–8.PubMedGoogle Scholar
  8. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946–51.PubMedCrossRefGoogle Scholar
  9. Cunha GR, Lung B. Possible influence of temporal factors in androgenic responsiveness of urogenital tissue recombinants from wild-type and androgen-insensitive (TFM) mice. J Exp Zool. 1978;205:181–93.PubMedCrossRefGoogle Scholar
  10. Cunha GR, Hayward SW, Dahiya R, Foster BA. Smooth muscle-epithelial interactions in normal and neoplastic prostatic development. Acta Anat. 1996;155:63–72.PubMedCrossRefGoogle Scholar
  11. Dalrymple S, Antony L, Xu Y, Uzgare AR, Arnold JT, Savaugeot J, Sokoll LJ, de Marzo AM, Isaacs JT. Role of Notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells. Cancer Res. 2005;65:9269–79.PubMedCrossRefGoogle Scholar
  12. Doehring CB, Sanda MG, Partin AW, Sauvageot J, Juo H, Beaty TH, Epstein JI, Hill G, Walsh PC. Histopathologic characterization of hereditary benign prostatic hyperplasia. Urology. 1996;48:650–3.PubMedCrossRefGoogle Scholar
  13. Dubrovska A, Elliott J, Salamone RJ, Kim S, Aimone LJ, Walker JR, Watson J, Sauveur-Michel M, Garcia-Echeverria C, Cho CY, Reddy VA, Schultz PG. Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma. Clin Cancer Res. 2010;16:5692–702.PubMedCrossRefGoogle Scholar
  14. Giles GG, Severi G, English DR, McCredie MRE, Macinnis R, Boyle P, Hopper JL. Early growth, adult body size and prostate cancer risk. Int J Cancer. 2003;103:241–5.PubMedCrossRefGoogle Scholar
  15. Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway IP, Witte ON. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad Sci U S A. 2008;105:20882–7.PubMedCrossRefGoogle Scholar
  16. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86:724–31.PubMedCrossRefGoogle Scholar
  17. Huggins C, Scott WW, Heinen JH. Chemical composition of human semen and of the secretions of the prostate and seminal vesicles. Am J Physiol - Leg Content. 1942;136:467–73.Google Scholar
  18. Isaacs JT. Prostate stem cells and benign prostatic hyperplasia. Prostate. 2008;68:1025–34.PubMedCrossRefGoogle Scholar
  19. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl. 1989;2:33–50.PubMedCrossRefGoogle Scholar
  20. Kellokumpulehtinen P. Correlation of embryonic-development and adult neoplastic changes of human-prostate. Eur Urol. 1989;16:386–90.Google Scholar
  21. Kramer G, Steiner GE, Handisurya A, Stix U, Haitel A, Knerer B, Gessl A, Lee C, Marberger M. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate. 2002;52:43–58.PubMedCrossRefGoogle Scholar
  22. Kyprianou N, Tu HC, Jacobs SC. Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol. 1996;27:668–75.PubMedCrossRefGoogle Scholar
  23. Lee KL, Peehl DM. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol. 2004;172:1784–91.PubMedCrossRefGoogle Scholar
  24. Lilja H, Oldbring J, Rannevik G, Laurell CB. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human-semen. J Clin Investig. 1987;80:281–5.PubMedCrossRefGoogle Scholar
  25. Lin VK, Wang D, Lee IL, Vasquez D, Fagelson JE, McConnell JD. Myosin heavy chain gene expression in normal and hyperplastic human prostate tissue. Prostate. 2000;44:193–203.PubMedCrossRefGoogle Scholar
  26. Lin VK, Wang S-Y, Vazquez DV, Xu CC, Zhang S, Tang L. Prostatic stromal cells derived from benign prostatic hyperplasia specimens possess stem cell like property. Prostate. 2007;67:1265–76.PubMedCrossRefGoogle Scholar
  27. Litman HJ, Bhasin S, O’Leary MP, Link CL, McKinlay JB. An investigation of the relationship between sex-steroid levels and urological symptoms: results from the Boston Area Community Health survey. BJU Int. 2007;100:321–6.PubMedCrossRefGoogle Scholar
  28. Litvinov IV, Vander Griend DJ, Xu Y, Antony L, Dalrymple SL, Isaacs JT. Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Res. 2006;66:8598–607.PubMedCrossRefGoogle Scholar
  29. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, Wiggins JF, Bader AG, Fagin R, Brown D, Tang DG. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011;17:211–5.PubMedCrossRefGoogle Scholar
  30. Marks LS, Trieger B, Dorey FJ, Fu YS, Dekernion JB. Morphometry of the prostate. 1. Distribution of tissue-components in hyperplastic glands. Urology. 1994;44:486–92.PubMedCrossRefGoogle Scholar
  31. Marks LS, Partin AW, Dorey FJ, Gormley GJ, Epstein JI, Garris JB, Macairan ML, Shery ED, Santos PB, Stoner E, Dekernion JB. Long-term effects of finasteride on prostate tissue composition. Urology. 1999;53:574–80.PubMedCrossRefGoogle Scholar
  32. Mcneal JE. Regional morphology and pathology of prostate. Am J Clin Pathol. 1968;49:347–57.PubMedGoogle Scholar
  33. McNeal J. Pathology of benign prostatic hyperplasia—insight into etiology. Urol Clin N Am. 1990;17:477–86.Google Scholar
  34. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma—correlation with histologic pattern and direction of spread. Am J Surg Pathol. 1988;12:897–906.PubMedCrossRefGoogle Scholar
  35. McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol. 2005;47:838–45.PubMedCrossRefGoogle Scholar
  36. Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int. 1999;84:976–81.PubMedCrossRefGoogle Scholar
  37. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84:767–801.PubMedCrossRefGoogle Scholar
  38. Parsons JK, Palazzi-Churas K, Bergstrom J, Barrett-Connor E. Prospective study of serum dihydrotestosterone and subsequent risk of benign prostatic hyperplasia in community dwelling men: the Rancho Bernardo Study. J Urol. 2010;184:1040–4.PubMedCrossRefGoogle Scholar
  39. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44(+)alpha 2 beta 1(+) cell population is enriched in tumor-initiating cells. Cancer Res. 2007;67:6796–805.PubMedCrossRefGoogle Scholar
  40. Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med. 1987;317:599–604.PubMedCrossRefGoogle Scholar
  41. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–7.PubMedCrossRefGoogle Scholar
  42. Price H, McNeal JE, Stamey TA. Evolving patterns of tissue composition in benign prostatic hyperplasia as a function of specimen size. Hum Pathol. 1990;21:578–85.PubMedCrossRefGoogle Scholar
  43. Ravenna L, Lubrano C, Disilverio F, Vacca A, Felli MP, Maroder M, Deramo G, Sciarra F, Frati L, Gulino A, Petrangeli E. Androgenic and antiandrogenic control on epidermal growth-factor, epidermal growth-factor receptor, and androgen receptor expression in human prostate-cancer cell-line LNCaP. Prostate. 1995;26:290–8.PubMedCrossRefGoogle Scholar
  44. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci. 2004;117:3539–45.PubMedCrossRefGoogle Scholar
  45. Roufosse CA, Direkze NC, Otto WR, Wright NA. Circulating mesenchymal stem cells. Int J Biochem Cell Biol. 2004;36:585–97.PubMedCrossRefGoogle Scholar
  46. Schuster GA, Schuster TG. The relative amount of epithelium, muscle, connective tissue and lumen in prostatic hyperplasia as a function of the mass of tissue resected. J Urol. 1999;161:1168–73.PubMedCrossRefGoogle Scholar
  47. Shapiro E, Becich MJ, Hartanto V, Lepor H. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol. 1992;147:1293–7.PubMedGoogle Scholar
  48. Sufrin G, Heston WDW, Hazra T, Coffey DS. Effect of radiation on prostatic growth. Investig Urol. 1976;13:418–23.Google Scholar
  49. Tsujimura A, Koikawa Y, Salm S, Takao T, Coetzee S, Moscatelli D, Shapiro E, Lepor H, Sun TT, Wilson EL. Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis. J Cell Biol. 2002;157:1257–65.PubMedCrossRefGoogle Scholar
  50. Tumbar T, Guasch G, Greco V, Blanpain C, Lowry WE, Rendl M, Fuchs E. Defining the epithelial stem cell niche in skin. Science. 2004;303:359–63.PubMedCrossRefGoogle Scholar
  51. Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I. Estradiol in elderly men. Aging Male. 2002;5:98–102.PubMedGoogle Scholar
  52. Weisser H, Krieg M. Fatty acid composition of phospholipids in epithelium and stroma of human benign prostatic hyperplasia. Prostate. 1998;36:235–43.PubMedCrossRefGoogle Scholar
  53. Xin L, Lukacs RU, Lawson DA, Cheng D, Witte ON. Self-renewal and multilineage differentiation in vitro from murine prostate stem cells. Stem Cells. 2007;25:2760–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  1. 1.Prostate Cancer Research Centre, Research Department of Urology, Charles Bell HouseUniversity College LondonLondonUK

Personalised recommendations